Trial reportJournal of veterinary internal medicine2017
Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.
Trial report in Journal of veterinary internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Is Rifampin (Rifampicin) Essential for the Treatment of Rhodococcus equi Infections in Foals? A Critical Review of the Role of Rifampin.Journal of veterinary pharmacology and therapeutics · 2025Review
- Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline againstFrontiers in pharmacology · 2024Article
- Investigation of the relationship between pulmonary lesions based on lung ultrasound and respiratory clinical signs in foals with suspected pulmonary rhodococcosis.Scientific reports · 2023Article
- Tulathromycin and Diclazuril Lack Efficacy againstPathogens (Basel, Switzerland) · 2023Article
- Characterizing the influence of various antimicrobials used for metaphylaxis against bovine respiratory disease on host transcriptome responses.Frontiers in veterinary science · 2023Article
- Less Typical Courses ofVeterinary sciences · 2022Article
- Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistantEFSA journal. European Food Safety Authority · 2022Article
- Efficacy of Ambroxol Hydrochloride Combined with Amoxicillin Potassium Clavulanate Combination on Children with Bronchopneumonia and Its Impact on the Level of Inflammatory Factors.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Prediction of Bronchopneumonia Inpatients' Total Hospitalization Expenses Based on BP Neural Network and Support Vector Machine Models.Computational and mathematical methods in medicine · 2022Article
- Comparative effectiveness of interventions for treating interdigital necrobacillosis in cattle: A network meta-analysis.Veterinarni medicina · 2021Article
- Current Trends in Understanding and Managing Equine Rhodococcosis.Animals : an open access journal from MDPI · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is conflicting data regarding the efficacy of tulathromycin for the treatment of foals with bronchopneumonia. HYPOTHESES: Tulathromycin is effective for the treatment of bronchopneumonia in foals and noninferior to the combination of azithromycin and rifampin. ANIMALS: A total of 240 foals on a farm endemic for infections caused by Rhodococcus equi.
methodsIn a controlled, randomized, and double-blinded clinical trial, foals with ultrasonographic pulmonary lesions (abscess score 10-15 cm) were allocated to 3 groups: 1-tulathromycin IM q 7 days (n = 80); 2-azithromycin-rifampin, orally q24h (n = 80); or 3-untreated controls (n = 80). Physical examination and thoracic ultrasonography were performed by individuals unaware of treatment group assignment. Foals that worsened were considered treatment failures and removed from the study.
resultsThe proportion of foals that recovered was significantly higher for foals treated with tulathromycin (70 of 79) or azithromycin-rifampin (76 of 80) compared to that of control foals (22 of 80). The difference in the percentage of efficacy of azithromycin-rifampin versus tulathromycin was 6.4% (90% CI = -0.72-13.5%). Given that the confidence interval crossed the predetermined noninferiority limit of 10%, the null hypothesis that the response rate in the azithromycin-rifampin group is superior to that of the tulathromycin group could not be rejected. Resolution of ultrasonographic lesions occurred faster in foals treated with azithromycin-rifampin than in foals treated with tulathromycin. CONCLUSION AND CLINICAL IMPORTANCE: Tulathromycin was effective for the treatment of bronchopneumonia in foals at this farm but not as effective as the combination of azithromycin-rifampin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.